MDxHealth
Molecular prostate-cancer tests for testing and treatment decisions.
Something off on this page? Send us feedback.
Profile
Offers molecular prostate-cancer tests, including Confirm mdx, GPS mdx and Exo mdx, to support testing and treatment decisions. It operates as one segment, with revenue primarily generated in the United States through tissue- and liquid-based testing.
Provides molecular diagnostics for prostate-cancer decision making. Its current menu includes Confirm mdx for men at risk of prostate cancer, GPS mdx for newly diagnosed men considering treatment or active surveillance, and Exo mdx, a liquid-based test.
Revenue is primarily generated in the United States, although the parent company is incorporated in Belgium. The business reports one segment and earns tissue-based and liquid-based testing revenue.
Operations depend on clinical-lab reimbursement, regulatory approvals and compliance, integration of acquired GPS and ExoDx assets, and creditor covenants. After a reimbursement-policy reversal, the company announced plans to discontinue Resolve UTI and close its Plano laboratory, concentrating on core prostate-cancer testing.
Company facts
Key statistics
Year to date −79.0% · Average volume (30d) 11.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 21, 2026 | BTIG | Reiterate | Buy | $4 | $2 |
| Aug 14, 2026 | Lake Street | Reiterate | Buy | $3 | |
| May 14, 2026 | BTIG | Reiterate | Buy | $15 | $4 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | −$0.19 | −$0.18 | +6.9% | $26.1M | $27.2M | +4.1% | +74.89% |
| May 13, 2026 | −$0.14 | −$0.19 | −31.4% | $30.9M | $23.9M | −22.6% | −49.50% |
| Nov 12, 2025 | −$0.12 | −$0.16 | −33.3% | $26.2M | $53.2M | +103.2% | −3.64% |
| Aug 5, 2025Q2 FY25 | −$0.13 | −$0.15 | −15.4% | $26.3M | $26.6M | +1.1% | +10.44% |
Financial highlights
| 12 quarters | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $31.4M | $38.7M | $42.0M | $48.1M | $26.6M | $54.7M | |
| Gross profit | $18.7M | $25.2M | $25.3M | $29.8M | $17.6M | $29.3M | |
| Operating income | −$16.5M | −$10.9M | −$14.0M | −$10.7M | −$1.9M | −$11.6M | |
| Net income | −$22.3M | −$20.8M | −$20.0M | −$18.0M | −$7.4M | −$18.8M | |
| Diluted EPS | −$1.02 | −$0.76 | −$0.73 | −$0.38 | −$0.30 | −$0.37 | |
| Gross margin | 59.5% | 65.1% | 60.4% | 62.0% | 66.0% | 53.6% | |
| Operating margin | -52.3% | -28.0% | -33.4% | -22.3% | -7.2% | -21.2% |
Balance sheet, Dec 31, 2025Cash & short-term investments $29.0M · Total debt $95.1M · Total assets $148.0M · Shareholders' equity −$12.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 51.36M · Float 41.57M · 80.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 31.65M | 33.20% | 13D | Aug 14, 2026 |
| MVM Partners, LLC · director | 6.90M | 13.44% | Form 4 | Aug 17, 2026 |
| Genomic Health, Inc. | 6.44M | 12.00% | 13G | Jan 16, 2026 |
| Awm Investment Company, Inc. | 5.22M | 10.17% | 13F | May 15, 2026 |
| Eric Bednarski · director | 4.70M | 9.15% | Form 4 | Apr 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | MVM Partners, LLC | director | +2,202,643 | $0.4540 |
Peers
- Veracyte
Biopsy-based prostate genomic classification for treatment decisions
- Myriad Genetics
Localized-prostate genomic risk stratification and treatment planning
- OPKO Health
Blood-based risk assessment before a prostate-biopsy decision
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MDxHealth | $0.7000 | −2.87% | $37.0M | — | — | 0.5 | +2.3% |
| Veracyte | $44.20 | +2.01% | $3.46B | 31.0 | 23.9 | 6.2 | +15.5% |
| Myriad Genetics | $3.16 | +0.48% | $298.5M | — | — | 0.4 | −10.5% |
| OPKO Health | $1.46 | −1.68% | $1.10B | — | — | 1.9 | +4.3% |
| Median | 31.0 | 23.9 | 1.9 | +4.3% |